Renal protection in IgA nephropathy requires strict blood pressure control

Nephrology Dialysis Transplantation

Volumn 20, Issue 8, 2005, Pages 1533-1539

  Nagy, Judit ^a   Kovács, Tibor ^a   Wittmann, István ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Ambulatory blood pressure monitoring; Hypertension; IgA nephropathy; Progression of renal diseases; Renin angiotensin aldosterone system; Renoprotection

Indexed keywords

ADRENALIN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIPORTER; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; INDOMETACIN; IRBESARTAN; LITHIUM ION; LOSARTAN; NIFEDIPINE; SODIUM ION;

ADRENALIN BLOOD LEVEL; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CIRCADIAN RHYTHM; CLINICAL TRIAL; CREATININE BLOOD LEVEL; EDITORIAL; HUMAN; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; IMMUNOGLOBULIN A NEPHROPATHY; INCIDENCE; KIDNEY FAILURE; MALIGNANT HYPERTENSION; METABOLIC SYNDROME X; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SODIUM RESTRICTION; STEROID THERAPY;

ANIMALS; BLOOD PRESSURE; GLOMERULONEPHRITIS, IGA; HUMANS; KIDNEY; RENAL CIRCULATION; VITAMIN E;

EID: 26444513277     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfh920     Document Type: Editorial

References (36)

1. D'Amico G. Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors. Am J Kidney Dis 2000; 36: 227-237
2. Floege J, Feehally J. IgA nephropathy: Recent developments. J Am Soc Nephrol 2000; 11: 2395-2403
3. Subías R, Botey A, Darnell A et al. Malignant or accelerated hypertension in IgA nephropathy. Clin Nephrol 1987; 27: 1-7
4. Zucchelli P, Zuccala A, Mancini E. Hypertension in primary glomerulonephritis without renal insufficiency. Nephrol Dial Transplant 1989; 4: 605-610.
5. Valvo E, Gammaro L, Bedogna V et al. Hypertension in primary immunoglobulin A nephropathy (Berger's disease): Hemodynamic alterations and mechanisms. Nephron 1987; 45: 219-223
6. Boero R, Degli Esposti E, Fabbri A et al. Increased sodium-lithium countertransport activity in red cells of IgA nephropathy patients. Kidney Int 1991; 40: 1118-1122
7. Konishi Y, Okada N, Okamura M et al. Sodium sensitivity of blood pressure appearing before hypertension and related to histological damage in immunoglobulin A nephropathy. Hypertension 2001; 38: 81-85
8. Eiro M, Katoh T, Sakuma Y et al. Insulin resistance highly associates with hypertension in IgA nephropathy. Clin Nephrol 2003; 59: 71-78
9. Fliser D, Pacini G, Engelleiter R et al. Insulin resistance and hyperinsulinemia ae already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-1347
10. Syrjänen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000; 15: 34-42
11. Bonnet F, Deprele C, Sassolas A et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001; 37: 720-727
12. Csiky B, Kovács T, Wagner L et al. Ambulatory blood pressure monitoring and progression in patients with IgA nephropathy. Nephrol Dial Transplant 1999; 14: 86-90
13. Stefanski A, Schmidt KG, Waldherr R et al. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 1996; 50: 1321-1326
14. Szelestei T, Kovács T, Barta J et al. Circadian blood pressure changes and cardiac abnormalities in IgA nephropathy. Am J Nephrol 1999; 19: 546-551
15. K/DOQI. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis 2002; 39 [Suppl 1]: S1-S266
16. Kocks MJA, De Zeeuw D, Navis GJ. Optimal blood pressure control and antihypertensive regimens in hypertensive renal disease: The potential of exploring the mechanisms of response. Curr Opin Nephrol Hypertens 2002; 11: 135-140
17. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal disease. Lancet 2001; 357: 1601-1608
18. Kanno Y, Okada H, Saruta T et al. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: A 3-year follow-up. Clin Nephrol 2000; 54: 360-365
19. Osawa Y, Narita I, Imai N et al. Determination of optimal blood pressure for patients with IgA nephropathy based on renal histology. Hypertens Res 2001; 24: 89-92
20. Pozzi C, Andrulli S, Del Vecchio L et al. Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15: 157-163
21. Hebert LA, Wilmer WA, Falkenhain ME et al. Renoprotection: One or many therapies? Kidney Int 2001; 59: 1211-1226
22. Wilmer WA, Rovin BH, Hebert CJ et al. Management of glomerular proteinuria: A commentary. J Am Soc Nephrol 2003; 14: 3217-3232
23. Wolf G. Molecular mechanism of angiotensin II in the kidney: Emerging role in the progression of renal disease: Beyond haemodynamics. Nephrol Dial Transplant 1998; 13: 1131-1142
24. Coppo R, Amore A, Hogg R et al. Idiopathic nephropathy with IgA deposits. Pediatr Neprol 2000; 15: 139-150
25. Laville M, Alamartine E. Treatment options for IgA nephropathy in adults: A proposal for evidence-based strategy. Nephrol Dial Transplant 2004; 19: 1947-1951
26. Reddan DN and Owen WF. IgA nephropathy and inhibitors of the renin angiotensin system. Is reduction in proteinuria adequate proof of efficacy? Am J Kidney Dis 2001; 38: 182-185
27. Cattran CD, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994; 23: 247-254
28. Maschio A, Cagnoli L, Claroni F et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: A multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 1994; 9: 265-269
29. Praga M, Gutiérrez E, González E et al. Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-1583
30. Perico N, Remuzzi A, Sangalli F et al. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 1998; 9: 2308-2317
31. Russo D, Minutolo R, Pisani A et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001; 38: 18-25
32. Song JH, Lee SW, Suh JH et al. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-β excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin Nephrol 2003; 60: 318-326
33. Rekola S, Bergstrand A, Bucht H. Deterioriation rate in hypertensive IgA nephropathy: Comparison of a converting enzyme inhibitor and β-blocking agents. Nephron 1991; 59: 57-60
34. Bannister KM, Weaver A, Clarkson AR et al. Effect of angiotensin-converting enzyme and calcium channel inhibiton on progression of IgA nephropathy. Contrib Nephrol 1995; 111: 184-193
35. Park HC, Xu ZG, Choi S et al. Effect of losartan and amlodipine on proteinuria and transforming growth factor-β1 in patients with IgA nephropathy. Nephrol Dial Transplant 2003; 18: 1115-1121
36. Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet, 2003; 361: 117-124